Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOSEASONIQUE vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and drospirenone; ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; drospirenone is a progestin with anti-mineralocorticoid and anti-androgenic activity.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris in women at least 14 years old who have achieved menarche and desire an oral contraceptive,Treatment of premenstrual dysphoric disorder (PMDD) in women who choose to use an oral contraceptive
Prevention of pregnancy (FDA-approved)
One tablet (ethinyl estradiol 0.02 mg/levonorgestrel 0.1 mg) orally once daily for 21 days, followed by 7 days of placebo.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal elimination half-life is 12-15 hours, supporting once-daily dosing.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol: primarily metabolized by CYP3A4, undergoes conjugation and enterohepatic recirculation. Drospirenone: extensively metabolized by CYP3A4, with minor involvement of CYP1A1 and CYP2C9; forms two major metabolites (dihydrodrospirenone and drospirenone sulfate) that are not pharmacologically active.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal: ~50% as metabolites; fecal: ~30% as metabolites; biliary: minor.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Ethinyl estradiol: ~97% bound to albumin; progestin: ~99% bound to SHBG and albumin.
~99% bound to serum albumin and sex hormone-binding globulin.
Ethinyl estradiol: 4-5 L/kg; progestin: 2-3 L/kg; indicates extensive tissue distribution.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: ~40-60% for ethinyl estradiol due to first-pass metabolism; progestin: >80%.
Oral: ~70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in Child-Pugh Class B or C hepatic impairment; no specific dose adjustment defined for mild impairment but use with caution.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Safety and efficacy established in females of reproductive age; postmenarche use as per adult dosing. Not indicated before menarche.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in postmenopausal women; no geriatric-specific dosing.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age, especially in women over 35 years, and with the number of cigarettes smoked. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders (venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction),Hepatic disease (acute hepatitis, benign/malignant liver tumors),Hypertension (contraindicated if uncontrolled),Gallbladder disease,Carbohydrate/lipid metabolism effects,Headache (including migraine with focal aura),Uterine bleeding irregularities,Depression,Fluid retention,Ocular lesions (retinal thrombosis),Cervical cancer screening,Hereditary angioedema,Chloasma,Drug interactions (especially CYP3A4 inducers),Laboratory test interference (sex hormone-binding globulin, thyroid-binding globulin)
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer,Endometrial cancer or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Uncontrolled hypertension (BP ≥ 160/100 mm Hg),Diabetes with vascular involvement,Headache with focal neurological symptoms (migraine with aura) in women over 35,Major surgery with prolonged immobilization,Heavy smoking (≥15 cigarettes/day) in women over 35,Hypersensitivity to any component of the drug
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific dietary restrictions. Grapefruit may slightly increase ethinyl estradiol levels; consistent intake is advised. Alcohol in moderation does not affect efficacy. Always take with or without food consistently.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
Category X. Estrogen-progestin combinations are contraindicated in pregnancy. First trimester exposure associated with risk of congenital anomalies, particularly cardiac defects and limb reduction. Second and third trimester exposure may result in fetal harm including masculinization of female genitalia (progestin effect) and possible hepatic adenoma. Discontinue immediately if pregnancy occurs.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Excreted in breast milk. Estrogens may reduce milk quantity and quality. M/P ratio not established. Use not recommended during breastfeeding; alternative contraception advised.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
No dose adjustment applicable; drug is contraindicated in pregnancy. Discontinue immediately if pregnancy occurs.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
LOSEASONIQUE (ethinyl estradiol/levonorgestrel) is a combined oral contraceptive with a shortened hormone-free interval (2 days of placebo vs. typical 7 days) to reduce withdrawal bleeding duration and frequency. Counsel patients that spotting/breakthrough bleeding may occur more commonly in the first few cycles. It does not protect against STIs. Consider alternative contraception in patients with contraindications like smoking >35, hypertension, migraine with aura, or history of thromboembolism.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one tablet daily at the same time, even during placebo days, to maintain contraceptive efficacy.,If a dose is missed, follow the package instructions; missed pills increase pregnancy risk.,Spotting or breakthrough bleeding is common in the first 3 months and usually resolves.,Do not smoke while taking this medication, especially if over 35 years old, due to increased risk of blood clots.,This medication does not protect against HIV or other sexually transmitted infections.,Use back-up contraception (e.g., condoms) if you have vomiting or severe diarrhea for more than 48 hours.,Report any signs of blood clots: sudden chest pain, shortness of breath, leg swelling/pain, or severe headache.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOSEASONIQUE vs AFIRMELLE, answered by our medical review team.
LOSEASONIQUE is a Oral contraceptive that works by Combination of ethinyl estradiol and drospirenone; ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; drospirenone is a progestin with anti-mineralocorticoid and anti-androgenic activity.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOSEASONIQUE and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOSEASONIQUE is: One tablet (ethinyl estradiol 0.02 mg/levonorgestrel 0.1 mg) orally once daily for 21 days, followed by 7 days of placebo.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOSEASONIQUE and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOSEASONIQUE is classified as Category C. Category X. Estrogen-progestin combinations are contraindicated in pregnancy. First trimester exposure associated with risk of congenital anomalies, particularly cardiac defects an. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.